Elan granted US patent for new Alzheimer’s treatment

ELAN — which earlier this week announced tentative plans to partner with an international pharmaceutical company to boost its Alzheimer’s treatment roll-out — has won a significant US patent for one of its in-trial treatments for that condition.

This effectively guards against generic competition for the next 16 years.

The patent pertains to the Alzheimer’s treatment — code-named ELN-D005 — which Elan is developing in partnership with Canadian pharma, Transition Therapeutics. The drug is in the Phase-2 clinical trial phase and ranks as second in line (in terms of development levels) to AAB-001/Bapineuzumab in Elan’s busy pipeline of Alzheimer’s treatments.